CytomX Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
CytomX Therapeutics, Inc. (CTMX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $72.90 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-07
- CytomX Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$106.68M, a 337.66% decline year-over-year.
- CytomX Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $11.37M.
- CytomX Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $187.20M.
- CytomX Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$18.98M, a 335.08% decline year-over-year.
- CytomX Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $72.90M, a 62.65% increase from fiscal 2016.
- CytomX Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $44.82M.
- CytomX Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$4.57M, a 108.21% decline from fiscal 2014.
- CytomX Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $55.69M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$106.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$95.31M derived: sum of 2 quarters · filed 2018-03-07 | $91.89M derived: sum of 3 quarters · filed 2018-03-07 | $72.90M 10-K · filed 2018-03-07 |
| 2017-09-30 | $11.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $198.56M derived: sum of 2 quarters · filed 2017-11-07 | $179.58M 10-Q · filed 2017-11-07 | $224.47M derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | $187.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $168.22M 10-Q · filed 2017-08-07 | $213.10M derived: sum of 3 quarters · filed 2018-03-07 | $210.48M derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-03-31 | -$18.98M 10-Q · filed 2017-05-05 | $25.90M derived: sum of 2 quarters · filed 2018-03-07 | $23.28M derived: sum of 3 quarters · filed 2018-03-07 | $17.77M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-12-31 | $44.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $42.27M derived: sum of 2 quarters · filed 2018-03-07 | $36.75M derived: sum of 3 quarters · filed 2018-03-07 | $44.82M 10-K · filed 2018-03-07 |
| 2016-09-30 | -$2.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$8.14M derived: sum of 2 quarters · filed 2017-11-07 | -$64.00K 10-Q · filed 2017-11-07 | $23.57M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | -$5.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $2.56M 10-Q · filed 2017-08-07 | $26.19M derived: sum of 3 quarters · filed 2018-03-07 | $16.54M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $8.07M 10-Q · filed 2017-05-05 | $31.71M derived: sum of 2 quarters · filed 2018-03-07 | $22.05M derived: sum of 3 quarters · filed 2018-03-07 | $60.08M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $23.63M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $13.98M derived: sum of 2 quarters · filed 2018-03-07 | $52.00M derived: sum of 3 quarters · filed 2018-03-07 | -$4.57M 10-K · filed 2018-03-07 |
| 2015-09-30 | -$9.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $28.37M derived: sum of 2 quarters · filed 2016-11-03 | -$28.20M 10-Q · filed 2016-11-03 | -$17.12M derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-06-30 | $38.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$18.55M 10-Q · filed 2016-08-03 | -$7.47M derived: sum of 3 quarters · filed 2017-03-02 | |
| 2015-03-31 | -$56.58M 10-Q · filed 2016-05-06 | -$45.49M derived: sum of 2 quarters · filed 2017-03-02 | ||
| 2014-12-31 | $11.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $55.69M 10-K · filed 2017-03-02 | ||
| 2014-09-30 | $44.61M 10-Q · filed 2015-11-23 | |||
| 2013-12-31 | -$6.04M 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |